Roche Pharma AG. Summary of product characteristics. Mabthera 100 mg concentrate for solution for infusion. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed 23 Feb 2017.
Genentech, Inc. Rituxan (rituximab) prescribing information. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed 23 Feb 2017.
Generics and Biosimilars Initiative Online. EMA approval for rituximab biosimilar Truxima. 2017. http://www.gabionline.net/Biosimilars/News/EMA-approval-for-rituximab-biosimilar-Truxima. Accessed 23 Feb 2017.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed 23 Feb 2017.
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17:e502–9.
Generics and Biosimilars Initiative Online. Biosimilars approved in Europe. 2017. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed 23 Feb 2017.
Zarkali A, Karageorgopoulos DE, Rafailidis PI, Falagas ME. Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Curr Med Res Opin. 2014;30:471–80.
Bourdette D. Rituximab for treating multiple sclerosis: off-label but on target. Neurology. 2016;87:2070–1.
Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013;8:e66308.
Ryden-Aulin M, Boumpas D, Bultink I, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3:e000163.
Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016;9:180–8.
Gulacsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11(Suppl 1):S43–52.
National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: National clinical guideline for management and treatment in adults. Clinical guideline [CG79]. 2009. https://www.nice.org.uk/guidance/cg79/evidence/full-guideline-242191261. Accessed 23 Feb 2017.
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–22.
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2016. doi:10.1001/jamaoncol.2016.5688
Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–42.
Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–84.
Cancer Research UK. Chronic lymphocytic leukaemia (CLL) incidence statistics. 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll/incidence. Accessed 27 Jan 2017.
Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70:1445–76.
Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. Pharma Ther. 2010;35:148–57.
Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
National Institute for Health and Care Excellence. Rituximab for the first-line treatment of chronic lymphocytic leukaemia. Technology appraisal guidance [TA174]. 2009. https://www.nice.org.uk/guidance/ta174. Accessed 23 Feb 2017.
National Institute for Health and Care Excellence. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. Technology appraisal guidance [TA193]. 2010. https://www.nice.org.uk/guidance/ta193. Accessed 23 Feb 2017.
National Institute for Health and Care Excellence. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma. Technology appraisal guidance [TA226]. 2011. https://www.nice.org.uk/guidance/ta226. Accessed 23 Feb 2017.
National Institute for Health and Care Excellence. Rituximab for the first-line treatment of stage III-IV follicular lymphoma. Technology appraisal guidance [TA243]. 2012. https://www.nice.org.uk/guidance/ta243. Accessed 23 Feb 2017.
National Institute for Health and Care Excellence. Non-Hodgkin’s lymphoma: diagnosis and management. NICE guideline [NG52]. 2016. https://www.nice.org.uk/guidance/ng52. Accessed 23 Feb 2017.
Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, Leufkens HG. Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy. 2012;104:76–83.
Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.
Baer Ii WH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7:530–44.
Boncz I, Sebestyen A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006;368:917–8.
Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017;1:e000142.
Remuzat C, Urbinati D, Kornfeld A, et al. Pharmaceutical expenditure forecast model to support health policy decision making. J Mark Access Health Policy. 2014;2:23740. doi:10.3402/jmahp.v2.23740.
Urbinati D, Remuzat C, Kornfeld A, et al. EU pharmaceutical expenditure forecast. J Mark Access Health Policy. 2014:2. doi:10.3402/jmahp.v2.23738
Orlewska E, Gulacsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27:807–27.
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5–14.
Park W, Yoo DH, Suh CH, et al. Comparable time to retreatment with CT-P10 and innovator rituximab up to 2 years in patients with active rheumatoid arthritis [abstract no. THU0162]. Ann Rheum Dis. 2016;75(suppl 2):241–2.
Suh CH, Berrocal Kasay A, Chalouhi El-Khouri E, et al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks [abstract]. Arthritis Rheumatol. 2016;68:1634.
Yoo DH, Bozic Majstorovic L, Berrocal Kasay A, et al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks [abstract]. Arthritis Rheumatol. 2016;68:1635.
Yoo DH, Park W, Suh CH, et al. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks [abstract]. Arthritis Rheumatol. 2015; 67. 2015;67:1675.
Yoo DH, Park W, Suh CH, et al. Efficacy and safety of rituximab biosimilar candidate (CT-P10) and innovator rituximab in patients with rheumatoid arthritis: results from phase I randomized controlled trial over 72 weeks [abstract]. Arthritis Rheumatol. 2015;67:2058.
Yoo DH, Suh C, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:556–70.
Yoo D-H, Park W, Jeka S, et al. A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2013;65:1736.
Yoo D-H, Park W, Jeka S, et al. Impact of anti-drug antibody on efficacy and safety over week 24 in both CT-P10 and innovator rituximab treatment groups [abstract 1508]. Arthritis Rheumatol. 2014;66:S663–4.
Coiffier B, Sancho J-M, Jurczak W, et al. 1807 Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL). American Society of Hematology, 2016.
Kim WS, Ogura M, Buske C, et al. Global phase I/III pharmacokinetic and efficacy study comparing CT-P10, a biosimilar candidate to the rituximab reference product in patients with advanced stage follicular lymphoma (AFL). Blood. 2015;126:5111.
Roche. Finance report 2015. 2015. http://www.roche.com/dam/jcr:74af99eb-b51a-4f13-88b2-aacaf9f53c0c/en/fb15e.pdf. Accessed 23 Feb 2017.
Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.
Gang AO, Pedersen M, d’Amore F, et al. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leuk Lymphoma. 2015;56:2556–62.
Issa DE, van de Schans SA, Chamuleau ME, et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica. 2015;100:525–33.
Junlen HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29:668–76.
Knauf W, Abenhardt W, Dorfel S, et al. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015;33:15–22.
Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–86.
Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. 2013. http://eprints.lse.ac.uk/50513/. Accessed 23 Feb 2017.
Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5:e8933.
Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116–25.
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v83–90.
Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P, Péntek M. Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016;75(5):942–3.
Bocquet F, Loubiere A, Fusier I, Cordonnier AL, Paubel P. Competition between biosimilars and patented biologics: learning from European and Japanese experience. Pharmacoeconomics. 2016;34:1173–86.
Jahnsen J. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therap Adv Gastroenterol. 2016;9:322–9.
Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8.
ClinicalTrials.gov. The NOR-SWITCH Study (NOR-SWITCH). 2017. https://clinicaltrials.gov/ct2/show/NCT02148640. Accessed 31 Jan 2017.
Goll GL, Olsen IC, Jorgensen KK, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in norway [abstract]. Arthritis Rheumatol. 2016;68:19L.
Baji P, Gulacsi L, Lovasz BD, et al. Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scand J Gastroenterol. 2016;51:22–7.
Baji P, Gulacsi L, Golovics PA, et al. Perceived risks contra benefits of using biosimilar drugs in ulcerative colitis: discrete choice experiment among gastroenterologists. Value Health Reg Issues. 2016;10:85–90.
US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 20 Jan 2017.
Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol. 2010;85:771–80.
Leung LK, Mok K, Liu C, Chan SL. What do oncologists need to know about biosimilar products? Chin J Cancer. 2016;35:91.
Reinisch W, Louis E, Danese S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):17–26.
Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685–96.
Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohns Colitis. 2017;11:26–34.
van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12:33–40.
Kim J, Hong J, Kudrin A. 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheumatol. 2014;11:S512.
Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–71.
McCarthy G, Bitoun CE, Guy H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health. 2013;16:A558.
Lucioni C, Mazzi S, Caporali R. Budget impact analysis of infliximab biosimilar: the Italian scenery. GRHTA. 2015;2:78–88.
Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742–56.
Brodszky V, Rencz F, Pentek M, Baji P, Lakatos PL, Gulacsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16:119–25.
Kim JAHJ, Kudrin A. 5 year budget impact analysis of CT-P13 (infliximab) for the treatment of Crohn’s disease in UK, Italy and France. J Crohns Colitis. 2015;9(S144):137.
Severs M, Oldenburg B, van Bodegraven AA, Siersema PD, Mangen MJ. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289–96.
Ruff L, Rezk MF, Uhlig T, Gommers JW. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in Europe. Value Health. 2015;18:A639.
Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10:1599–609.
Sun D, Andayani TM, Altyar A, MacDonald K, Abraham I. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther. 2015;37:842–57.
Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:171–9.
Han S, Kim S, Kim J, et al. P582 The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016. J Crohns Colitis. 2017;11(suppl 1):S377.
Kim SC, Choi NK, Lee J, et al. Brief report: utilization of the first biosimilar infliximab since its approval in South Korea. Arthritis Rheumatol. 2016;68:1076–9.
EuroQol Research Foundation. What is EQ-5D? 2017. http://www.euroqol.org/. Accessed 22 Feb 2017.
Wisløff T, Hagen G, Hamidi V, Movik E, Klemp M, Olsen JA. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics. 2014;32:367–75.
Linde L, Sorensen J, Ostergaard M, Hetland ML. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. J Rheumatol. 2013;40:1479–86.
Best JH, Hornberger J, Proctor SJ, Omnes LF, Jost F. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health. 2005;8:462–70.
Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol. 2005;74:194–202.
Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera®) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol Assess. 2004;8:1–82.
Muller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57:1130–9.
Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 2014;32:193–207.
Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin’s lymphoma in the UK. Value Health. 2010;13:346–57.
Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19:570–6.